Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause C-reactive protein abnormal? 2,062 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 2,062 reports of C-reactive protein abnormal have been filed in association with TOFACITINIB (XELJANZ XR). This represents 1.3% of all adverse event reports for TOFACITINIB.

2,062
Reports of C-reactive protein abnormal with TOFACITINIB
1.3%
of all TOFACITINIB reports
932
Deaths
1,527
Hospitalizations

How Dangerous Is C-reactive protein abnormal From TOFACITINIB?

Of the 2,062 reports, 932 (45.2%) resulted in death, 1,527 (74.1%) required hospitalization, and 1,127 (54.7%) were considered life-threatening.

Is C-reactive protein abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 2,062 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause C-reactive protein abnormal?

METHOTREXATE (3,734) ADALIMUMAB (3,629) ETANERCEPT (3,592) ABATACEPT (3,402) LEFLUNOMIDE (3,279) TOCILIZUMAB (3,259) HYDROXYCHLOROQUINE (3,245) SULFASALAZINE (2,823) INFLIXIMAB (2,676) RITUXIMAB (2,608)

Which TOFACITINIB Alternatives Have Lower C-reactive protein abnormal Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All C-reactive protein abnormal Reports All Drugs Causing C-reactive protein abnormal TOFACITINIB Demographics